Sales of PCSK9 inhibitors fall short of expectations
Sales of two cholesterol-lowering medications that the FDA approved last summer have fallen far short of expectations, the Associated Press reports.
The FDA approval of the first two proprotein convertase subtilisin/kexin type 9 inhibitors (evolocumab and alirocumab) received national attention in 2015. However, the Associated Press notes that Sanofi reported meager alirocumab sales of just $10 million last quarter, while Amgen did not report evolocumab sales.
Read more at the link below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.